Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles.
Forde
Grace
G
New York University School of Medicine, USA.
D000279:Administration, Cutaneous; D000588:Amines / Q000627:therapeutic use; D000700:Analgesics / Q000145:classification* / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001168:Arthritis / Q000175:diagnosis; D017024:Chemotherapy, Adjuvant; D002908:Chronic Disease; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D003929:Diabetic Neuropathies / Q000175:diagnosis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D000077206:Gabapentin; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage; D017116:Low Back Pain / Q000175:diagnosis; D010146:Pain / Q000145:classification* / Q000188:drug therapy*; D010147:Pain Measurement; D010149:Postoperative Pain / Q000175:diagnosis; D017410:Practice Guidelines as Topic; D000069583:Pregabalin; D014947:Wounds and Injuries / Q000175:diagnosis; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D000588:Amines; D000700:Analgesics; D000701:Analgesics, Opioid; D000928:Antidepressive Agents; D003509:Cyclohexanecarboxylic Acids; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D008012:Lidocaine